BioCentury
ARTICLE | Company News

Sol, Agenus deal

September 7, 2015 7:00 AM UTC

Sol’s Diatheva s.r.l. subsidiary granted Agenus exclusive, worldwide rights to develop and commercialize undisclosed antibodies against carcinoembryonic antigen (CEA)-related cell adhesion molecule 1...